Qamar J. Khan

Qamar J. Khan

Hematology

2650 Shawnee Mission Parkway
Westwood, KS 66205

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor.

Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 14, 2025

Analysis of the Radiosensitivity Index in Paired Preneoadjuvant and Postneoadjuvant Therapy Triple-Negative Breast Cancer.

Analysis of the Radiosensitivity Index in Paired Preneoadjuvant and Postneoadjuvant Therapy Triple-Negative Breast Cancer.

Journal: International journal of radiation oncology, biology, physics

Published: March 03, 2025

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.

Journal: Cancer cell

Published: November 12, 2024

Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial.

Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial.

Journal: JCO oncology advances

Published: September 09, 2024

Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers.

Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers.

Journal: Nature communications

Published: April 04, 2024

Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.

Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 09, 2024

Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.

Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.

Journal: JAMA network open

Published: December 28, 2023

Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.

Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.

Journal: JAMA oncology

Published: November 22, 2023

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.

Journal: Cancer cell

Published: November 09, 2023

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer.

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer.

Journal: Scientific reports

Published: October 31, 2023

Use of Ultrasound and Ki-67 Proliferation Index to Predict Breast Cancer Tumor Response to Neoadjuvant Endocrine Therapy.

Use of Ultrasound and Ki-67 Proliferation Index to Predict Breast Cancer Tumor Response to Neoadjuvant Endocrine Therapy.

Journal: Healthcare (Basel, Switzerland)

Published: November 11, 2022

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease.

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease.

Journal: NPJ breast cancer

Published: September 09, 2022

Showing 1-12 of 42

Last Updated: 09/26/2026